Lunai Bioworks (NASDAQ:LNAI) Trading Down 2.1% – Here’s Why

Shares of Lunai Bioworks Inc. (NASDAQ:LNAI) fell 2.1% during mid-day trading on Thursday . The stock traded as low as $2.34 and last traded at $2.35. 39,837 shares were traded during mid-day trading, a decline of 92% from the average session volume of 488,892 shares. The stock had previously closed at $2.40.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LNAI. Weiss Ratings restated a “sell (e+)” rating on shares of Lunai Bioworks in a report on Wednesday, July 8th. Wall Street Zen raised Lunai Bioworks to a “sell” rating in a research report on Saturday, May 23rd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Lunai Bioworks Trading Down 2.1%

The company has a market capitalization of $10.65 million, a price-to-earnings ratio of -5.88 and a beta of 0.41. The stock’s fifty day simple moving average is $2.68 and its 200-day simple moving average is $2.94.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Lunai Bioworks stock. Millennium Management LLC purchased a new position in shares of Lunai Bioworks Inc. (NASDAQ:LNAI) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks at the end of the most recent reporting period. 71.41% of the stock is owned by institutional investors and hedge funds.

About Lunai Bioworks

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.